Gracell Biotechnologies Inc logo

Gracell Biotechnologies Inc Share Price (NASDAQ: GRCL)

▲

-10.25

(-100%)

Live

Last updated on

Bell Icon

The stock has been delisted from the stock exchange on 21 Feb 2024

Check the interactive Gracell Biotechnologies Inc Stock chart to analyse performance

Gracell Biotechnologies Inc Key Stats

Check Gracell Biotechnologies Inc key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$10.25
Open
$10.26
Market Capitalization
$989.9M
Today's Volume
$6.4M
Revenue TTM
$0.0
EBITDA
$-509.6M
Earnings Per Share (EPS)
$-0.97
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-31.57%

Global Institutional Holdings in Gracell Biotechnologies Inc

  • Name

    Holdings %

  • Vivo Capital, LLC

    11.27%

  • Temasek Holdings Ltd.

    10.25%

  • Orbimed Advisors, LLC

    9.64%

  • Hudson Bay Capital Management LP

    4.14%

  • TCG Crossover Management, LLC

    3.15%

  • Logos Global Management LP

    2.61%

Analyst Recommendation on Gracell Biotechnologies Inc Stock

Rating
Trend

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Gracell Biotechnologies Inc(by analysts ranked 0 to 5 stars)

About Gracell Biotechnologies Inc

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China.
Organization
Gracell Biotechnologies Inc
Employees
314
CEO
Dr. Wei Cao BM, Ph.D.
Industry
Miscellaneous

Important FAQs about investing in GRCL Stock from India :

What is Gracell Biotechnologies Inc share price today?

Gracell Biotechnologies Inc share price today is as on . Gracell Biotechnologies Inc share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Gracell Biotechnologies Inc share?

Gracell Biotechnologies Inc share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Gracell Biotechnologies Inc stock price today i.e. is trending at , lower by 100% versus the 52 week high.

How to invest in Gracell Biotechnologies Inc Stock (GRCL) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Gracell Biotechnologies Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Gracell Biotechnologies Inc Shares .

What is the minimum amount required to buy Gracell Biotechnologies Inc Stock (GRCL) from India?

Indian investors can start investing in Gracell Biotechnologies Inc (GRCL) shares with as little as ₹87.95 or $1 (as of October 21, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹879.50 in Gracell Biotechnologies Inc stock (as per the Rupee-Dollar exchange rate as on October 21, 2025). Learn more about fractional shares .

What are the returns that Gracell Biotechnologies Inc has given to Indian investors in the last 5 years?

Gracell Biotechnologies Inc stock has given 0.0% share price returns and 19.5% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?